Overview

DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Our study is a prospective, non-inferior, randomized phase II clinical trial, to compare the efficacy and safety profiles of DA versus DAC as adjuvant chemotherapy regimens for early-stage breast cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Cyclophosphamide
Docetaxel
Doxorubicin
Liposomal doxorubicin